Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.
Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, Russo S, Fusciello M, Hamdan F, Ferrari V, Ciampi D, Ilonen I, Räsänen J, Mäyränpää M, Partanen J, Koskela S, Honkanen J, Halonen J, Kuryk L, Rescigno M, Grönholm M, Branca RM, Lehtiö J, Cerullo V.
Chiaro J, et al. Among authors: kuryk l.
Nat Commun. 2023 Nov 3;14(1):7056. doi: 10.1038/s41467-023-42668-7.
Nat Commun. 2023.
PMID: 37923723
Free PMC article.